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Background: MicroRNAs (miRNAs) are small regulatory molecules which post-transcriptionally regulate mRNA
stability and translation. Several microRNAs have received attention due to their role as key metabolic regulators. In
spite of the high evolutionary conservation of several miRNAs, the role of miRNAs in lower taxa of vertebrates has
not been studied with regard to metabolism. The liver-specific and highly abundant miRNA-122 is one of the most
widely studied miRNA in mammals, where it has been implicated in the control of hepatic lipid metabolism.
Following our identification of acute postprandial, nutritional and endocrine regulation of hepatic miRNA-122
isomiRNA expression in rainbow trout, we used complementary in silico and in vivo approaches to study the role of
miRNA-122 in rainbow trout metabolism. We hypothesized that the role of miRNA-122 in regulating lipid metabolism
in rainbow trout is conserved to that in mammals and that modulation of miRNA-122 function would result in
altered lipid homeostasis and secondarily altered glucose homeostasis, since lipogenesis has been suggested to
act as glucose sink in trout.
Results: Our results show that miRNA-122 was functionally inhibited in vivo in the liver. Postprandial glucose
concentrations increased significantly in rainbow trout injected with a miRNA-122 inhibitor, and this effect
correlated with decreases in hepatic FAS protein abundance, indicative of altered lipogenic potential. Additionally,
miRNA-122 inhibition resulted in a 20% decrease in plasma cholesterol concentration, an effect associated with
increased expression of genes involved in cholesterol degradation and excretion.
Conclusions: Overall evidence suggests that miRNA-122 may have evolved in early vertebrates to support
liver-specific metabolic functions. Nevertheless, our data also indicate that metabolic consequences of miRNA-122
inhibition may differ quantitatively between vertebrate species and that distinct direct molecular targets of
miRNA-122 may mediate metabolic effects between vertebrate species, indicating that miRNA-122 - mRNA target
relationships may have undergone species-specific evolutionary changes.
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MicroRNAs (miRNAs) are a small class of non-coding
RNAs, which were first described in Caenorhabditis ele-
gans [1]. The class of miRNAs are posttranscriptional
regulators that mediate their physiological effects both
by target mRNA degradation and translational inhibition
[2]. Following their discovery, miRNAs have been identi-
fied in all vertebrate classes [3], and some miRNAs have* Correspondence: skiba@st.pee.inra.fr
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article, unless otherwise stated.been found to be expressed in a tissue-specific manner
[4]. In the mammalian liver, the miRNA expression pro-
file is dominated by a single sequence, miR-122, with ap-
proximately 50 000 copies per cell, representing close to
70% of the overall miRNAs species in this tissue [4]. In
mammals, miRNA-122 has been shown to be implicated
in the differentiation and maintenance of the hepatic
phenotype [5-8], and the regulation of metabolic liver
functions, especially lipid metabolism. Specifically,
miRNA-122 exerts a stimulatory role in lipogenesis and
cholesterol synthesis on the one hand, as well as an
inhibitory effect on β-oxidation capacity on the other
[9-11]. The tissue specific expression and high abundancetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of mammalian data which made miRNA-122 a ‘paradigm’
in miRNA research [12], make this miRNA a particularly
suitable target of study for comparative investigation. In
rainbow trout (Oncorhynchus mykiss), miRNA-122 is spe-
cifically localized to the liver [13], where it is highly abun-
dant [14], reflecting the situation in mammals. We have
previously shown that a specific isoform of miRNA-122,
omy-miRNA-122b, is postprandially regulated in rainbow
trout [14], and that this regulation depends on macronu-
trient composition and the endocrine factor insulin [15], a
key metabolic hormone. These findings led us to investi-
gate the function of miRNA-122 in rainbow trout, which,
in spite of its high degree of evolutionary conservation
[16], has not been characterized functionally in lower ver-
tebrates. Specifically, given its key implication in lipid me-
tabolism in higher vertebrates, we investigated the
hypothesis, that miRNA-122 is equally involved in the
regulation of lipid metabolism in trout, and that, via
modulation of lipid metabolism, it may secondarily regu-
late postprandial glucose metabolism in this species. Rain-
bow trout are carnivorous fish which are considered poor
utilizers of dietary carbohydrate [17], but several lines of
evidence have shown that induction of hepatic de novo
lipogenesis may act as a ‘glucose-sink’ in rainbow trout,
resulting in improved utilization of glucose. For example
an improved postprandial glucose profile was observed in
a ‘fat line’ of rainbow trout, characterized by increased ex-
pression of genes involved in de novo lipogenesis in the
liver, as well as increased muscle fat content [18,19].
Pharmacological modulation of rainbow trout by the anti-
diabetic drug metformin equally resulted in improved
postprandial glucose clearance, but in contrast to mam-
mals, this effect was not correlated with a repression of
hepatic gluconeogenic gene expression, but rather with an
induction of hepatic lipogenic gene expression [20], pro-
viding further evidence for an involvement of hepatic de
novo lipogenesis in glucose clearance in rainbow trout.
Acute administration of insulin in rainbow trout resulted
in increased fas gene expression, protein abundance and
enzymatic activity of FAS [21], and this acute, insulin-
stimulated FAS activity has been shown to increase hep-
atic triglyceride synthesis [22], which may, in part, contrib-
ute to improved glucose utilization induced by insulin
[21]. Lastly, a link between hepatic glucose utilization and
lipogenesis has also been shown at the metabolite level in
rainbow trout, as radioactively labeled glucose is dose-
dependently metabolized into triglycerides [23,24]. In
order to investigate a possible role for miRNA-122 in co-
ordinating postprandial glucose homeostasis through the
modulation of lipid metabolism, we used an in vivo ap-
proach by blocking the activity of miRNA-122 using a
short LNA-miRNA-122 inhibitor (LNA-122i) [25]. This
approach was complemented by in silico approaches topredict potential direct mRNA targets of miR-122 in rain-
bow trout, as well as to predict potentially regulated
pathways.
Results
Mature miRNA-122 is highly conserved in the
vertebrate lineage
The comparison of genomic sequences between several
fish species and higher vertebrates reveals complete evo-
lutionary conservation of the mature miRNA-122 se-
quence in vertebrates (Figure 1). The complimentary
strand, miRNA-122*, reveals an overall high conserva-
tion, however differences in nucleotides do exist among
species. The loop region linking both strands does not
display a high degree of sequence conservation, in line
with its function as a connecting structural component
in the hairpin structure (Figure 1). Precursors containing
miRNA-122 sequences are present in the genomes of all
vertebrate classes, but are absent from the sea lamprey
(Petromyzon marinus) genome (data not shown).
Predicted direct miRNA-122 target genes in rainbow trout
are enriched for proliferation and differentiation
processes, but not metabolism
The predicted direct miRNA-122 target genes in rainbow
trout (Additional file 1), are highly enriched for cell cycle
regulation, as well as cell proliferation and differentiation
processes (Figure 2). With the exception of glucose me-
tabolism, no distinct metabolic pathways feature in the
list of enriched target genes (SNEA cell process sheet,
line 31; Additional file 1).Hepatic omy-miRNA-122 isomiRNAs are functionally
inhibited in LNA-122i injected rainbow trout
Expression of all hepatic omy-miRNA-122 isomiRNA se-
quences, mature omy-miRNA-122 (df = 2; F = 6.824;
p < 0.01), omy-miRNA-122a (df = 2; F = 8.708; p < 0.01) and
omy-miRNA-122b (df = 2; F = 16.9; p < 0.01) was signifi-
cantly inhibited by LNA-122i treatments, irrespective of
dose (Figure 3A-C). Conversely, hepatic expression of omy-
miRNA-103 (df = 2; F = 0.041; p > 0.05), omy-miRNA-33
(df = 2, F = 1.999; p > 0.05) and omy-miRNA-21 (df = 2;
F = 1.127; p > 0.5) did not change significantly with LNA-
122i treatment (Figure 3D-F). The expression of individual
in silico predicted putative direct omy-miRNA-122 targets
in rainbow trout (Additional file 1) was measured to
validate the functionality of omy-miRNA-122 iso-
miRNA inhibition (Figure 3G-I). Hepatic expression
of fish-lineage specific cyp2k5 (df = 2; F = 6.53;
p < 0.01) increased significantly in fish injected with
either dose of LNA-122i (Figure 3G). A significant
de-repression of prostaglandin reductase 1, ptgr1
(df = 2; F = 10.09; p < 0.01; Figure 3H) was observed
Figure 1 Evolutionary conservation of pre-miRNA-122 in several vertebrate genomes. Sequences were retrieved from databases indicated
in the text and aligned using ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2). The complete conservation of the sequence of processed
miRNA-122 (highlighted in yellow) and the high conservation of its complementary strand miRNA-122* (highlighted in blue), is shown, as well as
the contribution of each sequence to the structure formed by the pre-miRNA-122 molecule.
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crease in archain1, arcn1 (df = 2; F = 8.209; p < 0.01;
Figure 3I).
Inhibition of miRNA-122 results in postprandial
hyperglycemia and decreased lipid availability
Plasma glucose concentration increased by 62% an 67%, re-
spectively with LNA-122i treatments and this increase was
significant (df = 2; F = 17.93; p < 0.01), irrespective of dose
(Figure 4A). With regard to lipid metabolites, both trigly-
ceride (−36%) and free fatty acid concentration (−46%) in
the plasma decreased in fish treated with the higher dose
of 25 μg/g LNA-122i, and both decreases were significant
(df = 2; F = 4.017; p < 0.05 and df = 2; F = 7.07; p < 0.01;
Figure 4B-C). The LNA-122i treatments lead to small
(−20%), but significant decreases in cholesterol (df = 2;
F = 3.038, p < 0.05), which, however, did not result in signifi-
cant pair-wise comparisons between individual treatment
groups (Figure 4D).Gene expression of hepatic metabolic markers is
regulated by miRNA-122 inhibition
Effect of omy-miRNA-122 inhibition on genes involved in
hepatic glucose metabolism
The effect of miRNA-122 inhibition on the expression of
genes involved in hepatic glucose metabolism, specific-
ally glucose import, glycolysis, gluconeogenesis and
glycogen metabolism was measured (Figure 5). The ex-
pression of the hepatic glucose transporter, glut2, did
not change significantly with LNA-122i treatment
(df = 2; F = 0.15; p > 0.862; Figure 5A). With regard to
gene expression of components of the glycolytic path-
way, a decrease in expression of glucokinase, gk, was ob-
served in fish injected with LNA-122i (df = 2; F = 7.025;
p < 0.05; Figure 5B), which was significantly decreased
when comparing fish injected with a dose of 25 μg/g
LNA-122i to saline-injected control fish. The expression
of neither liver phosphofructokinase, l-pfk (df = 2;
F = 0.774; p > 0.05; Figure 5C), nor pyruvate kinase, pk
Figure 2 Rainbow trout targets were identified and their functional enrichment for specific GO terms analyzed as described in the
text. A particular enrichment was noted for pathways involved in cell cycle regulation, cell proliferation and differentiation. Compared to the
comprehensive identification and validation of murine targets provided by Tsai et al. [30], 11% of rainbow trout targets were predicted to be
conserved targets. All of the conserved targets (dditl4, igf2, parp3, rtn3, serpinh1, socs6, ucp2a, slc2a1 and adam10) are enriched in pathways
regulating cell cycle, cell proliferation and differentiation, indicating an evolutionary conservation of specific miRNA-122 target relationships that
govern these processes.
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changes between treatment groups.
The expression of the gluconeogenic genes glucose-
6-phosphatase 1, g6pase1 (df = 2; F = 1.303; p > 0.05;
Figure 5E), fructose 1,6-bisphophatase, fbpase (df = 2;
F = 1.345; p > 0.05; Figure 5F), and mitochondrial
phosphoenolpyruvate carboxykinase, m-pepck (df = 2;
F = 1.371; p > 0.05; Figure 5G), did not change between
treatments. The expression of genes involved in glycogen
metabolism, glycogen synthase, gys2 (df = 2; F = 6.01
p < 0.05; Figure 5H) increased in fish treated with either
dose of LNA-122i, while glycogen phosphorylase, pyk,
(df = 2; F = 1.529 p > 0.5; Figure 5I), did not exhibit sig-
nificant changes between treatment groups.
Effect of omy-miRNA-122 inhibition on genes involved in
hepatic lipid metabolism
The effect of miRNA-122 inhibition on hepatic expres-
sion of genes involved in hepatic lipid metabolism, spe-
cifically lipogenesis, and β-oxidation, were analyzed
(Figure 6). The expression of sterol regulatory binding
protein 1c, srebp1c (df = 2; F = 6.176; p < 0.05; Figure 6A),
increased significantly compared to saline control in fish
injected with 25 μg/g LNA-122i. The expression of genes
implicated in lipogenesis did not change between treat-
ments for glucose-6-phosphate dehydrogenase, g6pdh
(df = 2; F = 0.153; p > 0.05; Figure 6B), or fatty acidsynthase, fas (df = 2; F = 0.317; p > 0.05; Figure 6C), but
the expression of acetyl-CoA-carboxylase, acc (df = 2;
F = 5.07;p < 0.05; Figure 6D), increased significantly in
LNA-122i treated fish, irrespective of the administered
dose. With regard to the expression of genes implicated
in fatty acid β-oxidation pathways, the expression of
carnithine palomtyl transporter isoforms, cpt1a (df = 2;
F = 1.905; p > 0.05; Figure 6E), and cpt1b (df = 2; F = 1.426;
p > 0.05; Figure 6F), did not change significantly with
treatment, while expression of 3-hydroxyacyl-CoA
dehydrogenase, hoad (df = 2; F = 3.897; p < 0.05;
Figure 6G), was significantly increased in fish injected
with 12.5 μg/g LNA-122i compared to saline-injected
control fish.
Effect of omy-miRNA-122 inhibition on genes in-
volved in hepatic cholesterol homeostasis The expres-
sion of hepatic genes implicated in cholesterol
synthesis, as well as export and degradation were in-
vestigated (Figure 7). A significant increase in sterol
regulatory binding protein 2, srebp2 (df = 2; F = 14.02;
p < 0.01; Figure 7A), was observed in fish treated with
25 μg/g LNA-122i when compared to controls. No
significant changes in the gene expression of hydroxy-
methylglutaryl CoA synthase, hmgcs (df = 2; F = 2.849;
p > 0.05; Figure 7B), hydroxymethylglutaryl CoA re-
ductase, hmgcr (df = 2; F = 0.864; p > 0.05; Figure 7C)


























































































































































































































































































































































Figure 3 Effect of LNA-122i treatment on hepatic omy-miRNA-122 isomiRNA expression (A-C), expression of hepatic, non-targeted
omy-miRNA species (D-F) and hepatic mRNAs predicted in silico to be targeted by omy-miRNA-122 isomiRNAs (G-I). Analyzed groups
consisted of n = 6 samples and data are depicted as mean ± S.E.M. for each group. Data were analyzed using one-way ANOVA and differences
between individual experimental groups assessed by Student-Newman-Keuls post-hoc test. Different letters indicate a significant difference
(p < 0.05) between experimental groups.
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pression of liver receptor x, lxr (df = 2; F = 4.5;
p < 0.05: Figure 7E), increased in LNA-122i treated
fish, irrespective of dose. No changes were observed
in cholesterol-7alpha-hydroxylase a, cyp7a, (df = 2;
F = 1.383; p > 0.05; Figure 7F), while cyp7b was in-
creased in fish treated with 25 μg/g LNA-122i com-
pared to other treatment groups (df = 2; F = 8.399;
p < 0.01; Figure 7F). The expression of ATP-binding
cassette sub-family G member 8, abcg8 (df = 2;
F = 1.175; p > 0.05; Figure 7G), did not change be-
tween treatment groups, while significant increases in
the expression of ATP-binding cassette sub-family G
member 5, abcg5 (df = 2; F = 4.035; p < 0.05; Figure 7G)
were found in trout injected with 25 μg/ g LNA-122i.
The expression of UDP glycosyltransferase 1 family,
polypeptide A3, utg1a3 (df = 2; F = 6.79; p < 0.01;Figure 7H), increased in trout injected with either
dose of LNA-122i.Effect of omy-miRNA-122 inhibition on hepatic insulin
signaling
As an important upstream regulator of postprandial meta-
bolic gene expression in the liver, we investigated the activ-
ity of the hepatic insulin signaling pathway. The activity of
the insulin pathway, as determined by the ratio phosphory-
lated/total protein, remained unaltered for all components
investigated (Figure 8A-G). Values from the statistical ana-
lysis are presented in Table 1. At the total protein level, a
significant decrease in total mTOR protein was observed
(df = 2; F = 5.285; p < 0.05; Figure 8B), which was signifi-
cantly reduced in fish treated with 12.5 μg/g LNA-122i


















































































































Figure 4 Effect of LNA-122i treatment on plasma concentrations of the metabolites glucose (A), triglycerides (B), free fatty acids (C)
and cholesterol (D). Analyzed groups consisted of n = 6 samples and data are depicted as mean ± S.E.M. for each group. Data were analyzed
using one-way ANOVA and differences between individual experimental groups assessed by Student-Newman-Keuls post-hoc test. Different
letters indicate a significant difference (p < 0.05) between experimental groups.
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abundance of key metabolic enzymes
Protein abundance of glucokinase, GK (Figure 9A), did
not change significantly between treatment groups, while
that of fatty acid synthase, FAS (Figure 9B), significantly
decreased in fish injected with either dose of LNA-122i,
compared to saline-injected control fish. Values from the
statistical analysis are presented in Table 1.
Discussion
The comparison of miRNA-122 across several vertebrate
species from genomic sequences reveals a complete con-
servation of miRNA-122 and high conservation of
miRNA-122* across vertebrate classes, while nucleotides
forming the loop between both pairing strands in the
pre-miRNA-122 molecule appear to be under less select-
ive pressure. The fact that miRNA-122 is absent from
the lamprey genome, but present in the elephant shark,
an elasmobranch, places the acquisition of miRNA-122
at the base of the vertebrate lineage evolution between
560 and 530 MYA [26]. Interestingly, and in contrast toother fish species, two loci for pre-miRNA-122 contain-
ing two completely conserved mature miRNA-122 se-
quences are present in the rainbow trout genome. This
likely reflects tetraploidization and re-diploidization that
occurred in the salmonid lineage 25–100 MYA [26], as
two sequences were also identified in the genome of an-
other salmonid species, the Atlantic salmon. However,
the functional consequences of this duplication remain
unknown, but provide for interesting future studies, es-
pecially given the relative rarity of miRNA duplication
events in teleost fish genomes [27]. Being liver-specific
and highly abundant in both rainbow trout [13,14] and
mammals [4], the postulated hypothesis that miRNA-122
evolved along with the vertebrate liver [16] is tempting.
Interestingly, no pre-miRNA-122 coding sequence was
found in the lamprey genome. While a liver is already
present in lampreys, which are believed to have sepa-
rated from the vertebrate lineage 560 MYA [26], its
phenotype is plastic across developmental stages, as it
undergoes biliary atresia and lamprey develop a compen-





















































































































































































































































































































Figure 5 Effect of LNA-122i treatment on hepatic expression of genes implicated in glucose metabolism. Expression of genes involved in
glucose transport (A), glycolysis (B-D), gluconeogenesis (E-G) and glycogen metabolism (H-I) was analyzed analyzed using one-way ANOVA and
differences between individual experimental groups assessed by Student-Newman-Keuls post-hoc test. Analyzed groups consisted of n = 6
samples and data are depicted as mean ± S.E.M. for each group. Different letters indicate a significant difference (p < 0.05) between
experimental groups.
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http://www.biomedcentral.com/1471-2164/15/70Since miRNA-122 has been shown to play a role in hep-
atocyte and biliary tract differentiation in zebrafish
[5,29], the evolution of miRNA-122 may indeed have
contributed to promote a stable hepatic phenotype seen
in vertebrates. Our in silico target prediction revealed
several specific trout mRNA targets of miRNA-122.
Compared to a comprehensive list of predicted and vali-
dated targets from miRNA-122 KO mice [30], a moder-
ate 11% of predicted targets were conserved targets
between both species. In spite of the moderate conser-
vation of direct miRNA-122 target genes between trout
and mice, the identified conserved targets, in additionto newly identified trout-specific targets, are enriched
for functional annotations indicative of cell proliferation
and differentiation processes. Therefore, the functional
prediction of miRNA-122 target genes in rainbow trout
is consistent with the development and maintenance of
a hepatic phenotype, similar to the experimentally vali-
dated function of miRNA-122 in mammals [6-8], and
more recently, zebrafish [5,29]. This finding is further
corroborated by the identification of rainbow trout
mRNA targets of miRNA-122 that are extra-hepatic and
tissue specific, such as, for example, gastric chitinase,



























































































































































































































































Figure 6 Effect of LNA-122i treatment on hepatic expression of genes implicated in lipid metabolism. Expression of genes with roles in
lipogenesis (A-D) and β-oxidation of fatty acids (E-G) was analyzed using one-way ANOVA and differences between individual experimental
groups assessed by Student-Newman-Keuls post-hoc test. Analyzed groups consisted of n = 6 samples and data are depicted as mean ± S.E.M. for
each group. Different letters indicate a significant difference (p < 0.05) between experimental groups.
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http://www.biomedcentral.com/1471-2164/15/70light chain, blood cell-expressed hemoglobin, and retina-
expressed rhodopsin (Additional file 1). This is in good
agreement with the postulated role of the tissue-specific
miRNA-122 which may in part maintain the hepatic
phenotype by repressing extra-hepatic tissue-specific
transcripts [31]. With the exception of glucose metabol-
ism (Additional file 1), little enrichment was observedfor predicted rainbow trout miRNA-122 target genes
with a role in metabolic pathways. This is consistent
with the finding that metabolic effects of miRNA-122
may be related to ‘indirect’ miRNA-122 target genes,
whose expression is modulated indirectly and as a con-
sequence of alteration of gene expression of direct target
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Figure 7 Effect of LNA-122i treatment on hepatic expression of genes implicated in hepatic cholesterol metabolism. Expression of genes
with roles in cholesterol synthesis (A-D), and cholesterol degradation and excretion (E-H), were analyzed using one-way ANOVA and differences
between individual experimental groups assessed by Student-Newman-Keuls post-hoc test. Analyzed groups consisted of n = 6 samples and data
are depicted as mean ± S.E.M. for each group. Different letters indicate a significant difference (p < 0.05) between experimental groups.
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http://www.biomedcentral.com/1471-2164/15/70studies in mammalian model systems have linked the
observed decrease in cholesterol and triglycerides in
these species to decreased expression of cholesterol and
fatty acid synthesis genes [9-11], without establishing alink to direct miRNA-122 target genes. Therefore, in
addition to validating individual predicted direct
miRNA-122 target gene expression to assess functional
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Figure 8 Effect of LNA-122i treatment on hepatic abundance and phosphorylation status of key elements of the hepatic insulin
signaling pathway. Phosphorylated and total protein abundance was measured for AKT (A), mTOR (B), S6 (C), AMPK (D), FoxO1A (E), GSK3β (F).
The individual graphs show the relative abundance of the phosphorylated form, the total protein and the ratio between the relative abundance
of the phosphorylated form and the relative abundance of the total protein. All protein abundances were normalized by β-tubulin abundance,
which did not change significantly with treatment (df = 2; F = 0.949; p > 0.05, data not shown).Representative Western Blot images are shown (G).
Analyzed groups consisted of n = 6 samples and data are depicted as mean ± S.E.M. for each group. Data were analyzed using one-way ANOVA
and differences between individual experimental groups assessed by Student-Newman-Keuls post-hoc test. Different letters indicate a significant
difference (p < 0.05) between experimental groups.
Mennigen et al. BMC Genomics 2014, 15:70 Page 10 of 20
http://www.biomedcentral.com/1471-2164/15/70on analyzing the expression of non-target markers of
key hepatic metabolic pathways to elucidate the under-
lying (indirect) molecular mechanisms for the observed
metabolic consequences in vivo. This approach is espe-
cially suitable in studying metabolic pathways, which, al-
beit not exclusively, are highly regulated at the level of
transcription [32]. It should be noted, however, that 3′
UTR annotation of trout mRNAs remains incomplete,
and that future studies may identify additional (metabolic)
miRNA-122 target genes in rainbow trout.Efficient miRNA-122 isomiRNA inhibition in rainbow trout
in vivo
Inhibition of miRNA-122 was confirmed by real-time RT-
PCR, which has been shown to be a monitoring technique
to assess efficient hepatic miRNA-122 inhibition in vivo
[10,11,33]. Given the fact that multiple isomiRNAs of
miRNA-122, likely resulting from posttranscriptional modi-
fications, had initially been described in both rainbow trout
as in mammals [13,34], we aimed to inhibit the expression
of not only the conserved mature omy-miRNA-122, but
Table 1 Statistical analysis associated with the Western
Blot measurements of (phosphorylated) proteins
involved in the insulin signaling pathway and metabolic
proteins shown in Figure 9 and 10
Protein One-way ANOVA
AKT-P df = 2; F = 0.130; p > 0.05
AKT-total df = 2; F = 0.399; p > 0.05
AKT-P/AKT-total df = 2; F = 0.461; p > 0.05
mTOR-P df = 2; F = 0.444; p > 0.05
mTOR-total df = 2; F = 5.285; p < 0.05*
mTOR-P/mTOR-total df = 2; F = 0.445; p > 0.05
S6-P df = 2; F = 0.786; p > 0.05
S6-total df = 2; F = 0.278; p > 0.05
S6-P/S6-total df = 2; F = 0.653; p > 0.05
AMPKα-P df = 2; F = 1.070; p > 0.05
AMPKα-total df = 2; F = 0.464; p > 0.05
AMPKα-P/AMPKα-total df = 2; F = 0.643; p > 0.05
FoxO1-P df = 2; F = 1.497; p > 0.05
FoxO1-total df = 2; F = 0.974; p > 0.05
FoxO1-P/FoxO1-total df = 2; F = 1.779; p > 0.05
GSK3β-P df = 2; F = 0.145; p > 0.05
GSK3α + β total df = 2; F = 0.339; p > 0.05
GSK3β-P/GSK3α + β total df = 2; F = 0.145; p > 0.05
GK df = 2; F = 1.652; p > 0.05
FAS df = 2; F = 14.2; p < 0.001**
β-tubulin df = 2; F = 0.409; p > 0.05
The asterisk symbol (*) indicates a significant difference at p < 0.05, while two
asterisks (**) denote a significant difference at p < 0.001).
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http://www.biomedcentral.com/1471-2164/15/70also of the identified trout isomiRNAs, specifically omy-
miRNA-122a and omy-miRNA-122b. The miRNA-122 iso-
miRNAs share a common miRNA-122 seed sequence,
hence all are considered functional. However, possible di-














































































Figure 9 Effect of LNA-122i treatment on hepatic protein abundance
Densitometry results for Glucokinase, GK (A) and fatty acid synthase,
(C). Analyzed groups consisted of n = 6 samples and data are depicted as
ANOVA and differences between individual experimental groups assessed
significant difference (p < 0.05) between experimental groups.currently debated [34,35]. With regard to the study of regu-
latory effects of miRNA-122 in rainbow trout, the fact that
all three isoforms were found to be inhibited by LNA-122i
treatment ensures that no uninhibited functional isoforms
of miRNA-122 can compensate for the inhibited mature
form. In order to exclude potential effects of the LNA-122i
treatment on the canonical miRNA pathway, we assessed
the expression of non-targeted omy-miRNA-103, omy-
miRNA-21 and omy-miRNA-33, and found no significant
changes in expression between treatment groups. Lastly, as
an index of functional inhibition of miRNA-122, we vali-
dated an expected de-repression of in silico predicted, rain-
bow trout-specific targets of miRNA-122, including the fish
specific cytochrome cyp2k5, the prostaglandin reductase
ptgr1, and archain arcn1. For all three genes, a significant
de-repression was confirmed, irrespective of the dose ad-
ministered. Overall, our study reveals the feasibility of silen-
cing approaches in fish, an area comparatively understudied
[36,37], in spite of its great potential for comparative
physiology.
Inhibition of miRNA-122 results in postprandial hypergly-
cemia and decreased availability of lipids in the plasma
The dose-independent >60% increase in blood glucose
found in trout subjected to miRNA-122 inhibition has
not been described in mice, where miRNA-122 inhib-
ition resulted only in slight, but non-significant, trends
for increases in plasma glucose [9]. Interestingly, in an
acute glucose tolerance test in miRNA-122 knock-out
mice, Tsai and colleagues [30] observed small, but statis-
tically significant increases in acute postprandial (60–
120 min) measurements of blood glucose after glucose
injection, emphasizing the importance of sampling time
when analyzing particular metabolic endpoints. Never-
theless the increase appears to be stronger in rainbow
trout than in mammalian model systems, especially




























of key factors in hepatic glucose and lipid metabolism:
FAS (B) are shown, as well as representative Western Blot images
mean ± S.E.M. for each group. Data were analyzed using one-way
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Figure 10 Schematic representation of the experimental design for the in vivo study of metabolic effects of LNA-122i. Detailed
explanations are provided in the text. Samples analyzed in this study stem from postprandial fish fed 4 h before sacrifice.
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compared to mice injected with a LNA-122i which dis-
play reversible metabolic effects [11,30]. With regard to
plasma triglyceride concentration, the significant >30%
decrease in plasma triglyceride concentration in trout
treated with 25 μg/g LNA-122i is similar to a significant
40% decrease observed in mice treated with the same
dose of LNA-122i and subjected to a similar injection
protocol [10]. Similarly, recent studies on miRNA-122
knock-out models detected significant, persistent de-
creases in serum triglycerides [30]. The concentration of
free fatty acids in trout plasma paralleled the observed
plasma concentration of triglycerides. The plasma con-
centration of free fatty acids decreased significantly
(<40%) in trout injected with the higher dose of 25 μg/g
of LNA-122i. This is in contrast to findings in mamma-
lian model systems, where only a very slight, non-
significant decrease of free fatty acids in mice injected
with miRNA-122 inhibitors have been found [9]. A de-
crease of 20% in plasma cholesterol concentration was
observed in trout injected with LNA-122i, irrespective of
the dose administered. This decrease in plasma choles-
terol concentrations was significant but slight, and post-
hoc comparisons did not resolve differences between
individually compared treatment groups. In mammalian
miRNA-122 inhibition studies [9-11], as well as recent
mammalian knock-out models [30,38], reductions of
cholesterol between 20-50% have been observed, making
it the most consistently observed metabolic effect of
miRNA-122 inhibition in mammals. In all cases, the ef-
fects on plasma cholesterol are long lasting but revers-
ible [11] and interestingly, similar to our study, an
increase in dose does not lead to further decrease in
plasma cholesterol concentration, suggesting a satur-
ation effect [10]. While the metabolic effects of miRNA-
122 inhibition in trout are largely in line with the effects
reported in the mammalian literature, the quantitative
nature of these effects appears to differ slightly between
trout and mammalian model systems. Nevertheless,
these differences should be interpreted with caution,
since the measured metabolites are subject to acute, buttemporally different, postprandial changes in mammals
[39] as in trout [40]. Hence, the fact that our study was
specifically designed to target acute postprandial changes
is in contrast to most published literature using mam-
malian model systems, where animals were either fasted,
or the information of the feeding times was not indi-
cated [9-11]. These differences in experimental design
may have contributed to different measurements of
plasma metabolite concentrations.
Characterization of potential hepatic molecular
mechanisms underlying the metabolic phenotype
In order to establish potential underlying molecular
mechanisms in the development of the observed meta-
bolic phenotype in rainbow trout experiencing miRNA-
122 inhibition, we investigated specific metabolic
markers in the hepatic tissue.
Postprandial hyperglycemia in trout with miRNA-122
inhibition decreases hepatic gk expression and FAS
protein levels
To investigate molecular mechanisms underlying the ob-
served postprandial hyperglycemia, we investigated hep-
atic gene expression for transcripts implicated in the
hepatic intermediary metabolism of glucose and lipids,
as transcriptional regulation of these pathways plays an
important role in regulating systemic glucose homeosta-
sis [32]. Specifically, we investigated hepatic genes with a
role in (1) glucose utilization (glucose uptake, glycolysis
and glycogenesis) and (2) hepatic glucose production
(gluconeogenesis and glycogenolysis). Additionally, to
test our hypothesis that miRNA-122 alters glucose me-
tabolism by regulating hepatic de novo lipogenesis, we
quantified responses for genes involved in lipogenesis
and fatty acid oxidation. The effect of miRNA-122 inhib-
ition on hepatic protein abundance of key enzymes of
both, the glycolytic (GK), and lipogenic pathway (FAS)
were measured, to account for potential effects of
miRNA-122 at the protein level in these pathways.
With respect to hepatic glucose catabolism, we identi-
fied a significant decrease in gk mRNA expression in fish
Table 2 Sequences and conditions for new primers used in SYBR Green real-time RT-PCR assays
Gene Forward primer (5′3′) Reverse primer (3′5′) Tm
(°C)
Gene bank or SIGENAE
accession number
Amplicon size (bp)
omy-miRNA-122 TGGAGTGTGACAATGGTGTTTGT Poly T Primer (Invitrogen) 60 - -
cyp2k5 CTCACACCACCAGCCAAGAC CGTCAGCAGAGGTAACACATCAG 60 NM_001124742 76
ptgr1 CAGTGATTGTGGATGGAGGAG CCTTGATCTTGGCGATCTGT 60 NM_001124634 238
arcn1 AGCCTCACTTGTGGGAGAGA CTTGTCACCGTTGTTGATGG 60 NM_001164069 119
Gs AAGATATGGAGGCGGAGAGG GATCTCAAGGACCAGGGTTG 60 BX299627.p.om.8 152
Pygl AACCGACACCTCCACTTCACC CCTGCATCTTCCTCCATCTC 60 BX882218.p.om.8 296
srebp2 TAGGCCCCAAAGGGATAAG TCAGACACGACGAGCACAA 60 BX859204.p.om.8 161
Hmgcs AGTGGCAAAGAGAGGGTGTG TTCTGGTTGGAGACGAGGAG 60 CX251971.p.om.8 298
Hmgcr GAACGGTGAATGTGCTGTGT GACCATTTGGGAGCTTGTGT 60 AB218825.p.om.8 216
dhcr7 GTAACCCACCAGACCCAAGA CCTCTCCTATGCAGCCAAAC 60 CA376644.p.om.8 289
cyp7a ACGTCCGAGTGGCTAAAGAG GGTCAAAGTGGAGCATCTGG 60 AB675933 111
cyp7b ACAGAGACCTCACCTTCACCA GATCTCCCTTCCTCACTCCA 60 F6VG15V01BFI5C.p.om.8 171
abcg5 CACCGACATGGAGACAGAAA GACAGATGGAAGGGGATGAA 60 CU073172.p.om.8 268
abcg8 GATACCAGGGTTCCAGAGCA CCAGAAACAGAGGGACCAGA 60 FYV3OTN01BVHON.p.om.8 159
utg1a3 CCACCAGCAAGACAGTCTCA CAACAGCACAGTGGCTGACT 60 F6VG15V01BF6CZ.p.om.8 216
Gene bank accession number (www.ncbi.nlm.nih.gov/genbank) are provided when available. For the remaining sequences, accession numbers from the trout EST
database SIGENAE (www.sigenae.org) are provided. Additional primer sequences have been previously published and can be found in sources cited in the text.
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longs to the hexokinase family and is highly expressed in
the liver; its specific properties allow the hepatic influx
of glucose across the physiological range of blood
glucose concentration [41]. Functionally, glucokinase
therefore represents an important node in glucose me-
tabolism, channeling postprandial hepatic glucose flux
towards oxidative pathways, but also towards energy
storage in the form of glycogen deposition and de novo
lipid synthesis, the latter of which is subsequently
exported to adipose tissue for storage. It can therefore
be considered the first step of lipogenesis. Liver specific
knock-out [42] or overexpression [43,44] of gk in mam-
malian model systems provide unequivocal evidence that
hepatic GK regulates blood glucose homeostasis by lim-
iting hepatic glucose utilization for glycogen synthesis
and the de novo lipogenic pathway. In rainbow trout, gk
expression is, as in mammals, mainly hepatic, and is
reduced by fasting and induced by (carbohydrate) feed-
ing [45]. Interestingly, in trout, unlike in mammals, car-
bohydrates are capable of stimulating gk expression
independently of insulin [46,47], and thus gk is consid-
ered a glucose sensor [46,47]. The diminished levels of
gk mRNA may be indicative of a reduced postprandial
glucose sensing capacity in trout experiencing miRNA-
122 inhibition. However, the extrapolation of functional
consequences, as seen in mammalian knock-out models
is difficult based on our data, since, at the protein level,
hepatic GK abundance did not change between control
and LNA-122i injected fish. Further time course studies are
required to address whether the decreased postprandialinduction of the glucosensor gk results in temporally
delayed changes in GK protein concentration. With re-
gard to glycogen synthesis, a paradoxical increase in
mRNA abundance of hepatic glycogen synthase, the
rate-limiting enzyme in glycogen deposition, was ob-
served in trout injected with either dose of LNA-122i.
While these data do not correspond to the observed in-
crease in plasma glucose, the fact that fish were sam-
pled 5 d following the last injection of the LNA-122i
may reflect that the induction of gys2 represents a
counter-regulatory response to cope with hypergly-
cemia. The observed change in indicators of glycogen
metabolism, particularly in the form of increased gys2
expression, is in contrast to findings from a recent
mouse miRNA-122 knock-out model, where mild post-
prandial hyperglycemia was correlated with decreased
hepatic glycogen storage and decreased protein abun-
dance and activity of glycogen synthase [30]. Unfortu-
nately, due to the limited hepatic size in juvenile fish,
we were unable to use the samples to measure hepatic
glycogen content directly in addition to other hepatic
measurements, therefore the current results should be
interpreted with caution. Transcript markers of hepatic
anabolic pathways of glucose metabolism, specifically
at the level of gluconeogenesis and glycogenolysis, did
not change with LNA-122i treatment, indicating that
the observed postprandial hyperglycemia in LNA-122i
treated rainbow trout is, at the level of gene expression,
not related to hepatic glucose production or liberation.
In terms of lipid metabolism, miRNA-122 inhibition in
trout resulted in significant increases in the expression
Mennigen et al. BMC Genomics 2014, 15:70 Page 14 of 20
http://www.biomedcentral.com/1471-2164/15/70of genes involved in lipogenesis (srebp1c, acc). The expres-
sion pattern observed for lipogenic genes is in contrast to
mammalian studies, where comparable miRNA-122 inhib-
ition results in decreased expression of lipogenic genes,
which correlate with decreased lipogenesis. Similarly, the
observed results are contrary to correlative evidence from
postprandial studies in rainbow trout [14], in which a posi-
tive correlation between omy-miRNA-122b and the lipo-
genic genes srebp1c has been described. Whether these
differences represent distinct, species-specific actions of
miRNA-122 in trout and mammalian models in the form
of a direct regulation of srebp1c or acc by miRNA-122 in
trout can currently not be predicted, as 3′UTR sequences
for either gene are currently unavailable. Differences in
the experimental protocol may also play a role in the ob-
served changes at the level of gene expression, especially
given that the metabolic consequences on plasma lipid
metabolites are largely consistent between trout and mam-
mals. While most studies in mammalian models investi-
gated gene expression shortly after the last injection
[9,10], our study design measured effects several days fol-
lowing the last injection. In line with this, the only tran-
scriptomic time-course study of miRNA-122 inhibition in
the liver of mice [11], revealed an initial inhibition of the
expression of the lipogenic gene srebp1c, which however
were not detected 1 wk following the treatment, in spite of
persisting, albeit less severe, miRNA-122 inhibition and
metabolic effects. The increased expression of acc, the rate
limiting enzyme in lipogenesis with both doses of LNA-
122i, may represent an adaptive response to cope with in-
creased glycemic load, similar to the effect observed for
gys2. Whether these mechanisms do indeed represent
physiological responses to maintain homeostasis in plasma
metabolites is not known, but may be delineated by fol-
lowing a time-course study, and through aforementioned
advances in annotation of 3′UTR sequences in trout.
While we did not observe changes in fas gene expression
between treatment groups, hepatic FAS abundance was
significantly inhibited at the protein level, similar to
miRNA-122 KO mice [30]. While this is indicative of re-
duced hepatic lipogenesis that is also observed in mamma-
lian model species [10], the current result does not
support the previously observed post-prandial and
insulin-mediated co-regulation of miRNA-122 and fas
[15]. The discrepancy between gene expression and
protein abundance data suggests that, in spite of the
previously observed co-regulation of specific miRNA-
122 isomiRNAs and fas in trout [14,15] and the ob-
served concurrent decrease of fas in miRNA-122
inhibited mammalian models [11], fas, at the level of
gene expression, may not be an indirect target of
miRNA-122 in rainbow trout. Alternatively, the LNA-
122i induced decrease of FAS, but not fas gene expres-
sion, may reflect temporally anterior changes in fasexpression/translation in unfed fish, which based on
the estimated half-life of FAS in mammals [48], may
still manifest themselves postprandially. As previously
noted, the limited amount of biological material in ju-
venile fish prevented the direct measurement of hep-
atic lipid contents, and without direct measurements
of hepatic lipid concentrations in addition to the mea-
sured plasma lipid concentrations, the current inter-
pretations on hepatic lipogenesis are inferred from
hepatic gene expression and protein data, as well as
plasma metabolite data. Therefore these data should be
interpreted cautiously.
Inhibition of omy-miRNA-122 does not alter hepatic
insulin signaling
Since miRNA-122 has been shown to stimulate hepatic
insulin signaling in mammals [49], and since a postpran-
dial coordination of glycolysis and lipogenesis is medi-
ated by the insulin pathway in rainbow trout [50], as in
mammals [51], we investigated the possible upstream in-
volvement of the insulin pathway in the observed meta-
bolic effects of miRNA-122 inhibition in rainbow trout.
In trout, similar to the situation in mammals, it has re-
cently been shown that inhibition of mTOR, a key node
in the insulin pathway, results in decreased expression
of hepatic gk and fas [50]. Given our hypothesis that
miRNA-122 may control glucose homeostasis through
regulation of glycolytic flux and subsequent de novo
lipogenesis in rainbow trout, we analyzed the postpran-
dial activity of hepatic insulin pathway with a particular
focus on the mTOR node. Indeed, recent evidence from
studies investigating miRNA-122 function in mammalian
model systems points to a stimulatory role for miRNA-
122 on the activity of the insulin pathway, and mTOR in
particular. Depletion of miRNA-122 in Hep2 cells re-
sulted in tyrosine phosphatase 1B induction and subse-
quently, reduced activity of the insulin pathway,
including a reduction in mTOR phosphorylation status
[49]. Inhibition of miRNA-122 equally resulted in in-
creased phosphorylation status of the metabolic sensor
AMPKα [10], which, in its phosphorylated form, acts
to inhibit mTOR signaling [52]. In our study, miRNA-
122 inhibition resulted in no notable differences in the
phosphorylation status of any component of the hepatic
insulin signaling pathway, indicating that the metabolic
effects observed in trout injected with LNA-122i are
not mediated by acute, postprandial alteration of hepatic
insulin signaling. Interestingly, the only detected change
in any of the components of the insulin pathway was
noted in the total protein abundance of mTOR, which
decreased significantly in trout injected with 12.5 μg/g
LNA-122i. This regulation however did not alter the
activity of the mTOR kinase, since the ratio of mTOR
phosphorylated form/total form did not change
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same index was unaffected for S6, a downstream target
of mTOR. While the physiological relevance of a de-
crease in total hepatic mTOR protein abundance is dif-
ficult to interpret, it may limit the maximum capacity
of downstream events such as lipogenesis. Whether
such decreases in total mTOR abundance can become
rate-limiting under physiological conditions, however,
is currently not known.
Genes involved in reverse cholesterol transport are
increased in miRNA-122-inhibited fish
The inhibition of miRNA-122 resulted in slightly, but
significantly, reduced plasma cholesterol levels, mirror-
ing findings from numerous studies in mammalian
models [9-11,30]. In contrast to the identification of a
decrease in cholesterol biosynthesis genes in these stud-
ies, which were considered to be a likely cause for the
observed decrease in plasma cholesterol, genes impli-
cated in cholesterol synthesis either increased (srebp2)
or did not change their expression (dhr7; hcgr; hcgs) in
response to miRNA-122 inhibition in trout. Conversely,
miRNA-122 inhibition resulted in an increase in genes
implicated in cholesterol sensing (lxr), and excretion
(abca5, utg1a3). Interestingly, the expression of lxr, a nu-
clear receptor that serves as a rheostat for systemic chol-
esterol homeostasis [53-55], was increased in LNA-122i
injected trout, irrespective of dose. In the liver, LXR is
activated by its endogenous ligand oxysterol, which is
generated in conditions of high intracellular concentra-
tions of cholesterol [56]. In a positive feedback loop, ac-
tivated LXR stimulates its own expression, which is the
case in both mammals [57] and rainbow trout [58]. In
mammals, hepatic LXR regulates several effectors in-
volved in excreting cholesterol directly into the bile, or
metabolizing cholesterol into bile acids, which are subse-
quently conjugated and excreted via bile secretion [54].
Given the conservation of several targets of LXR be-
tween mammals and fish [59,60], we investigated the po-
tential induction of these downstream targets to provide
further evidence for an activation of LXR, and indeed
detected an increase in utg1a3, a bile conjugating en-
zyme with a proposed role in cholesterol elimination
[61,62]. Interestingly, a tendency for facilitated biliary
clearance has been measured in miRNA-122 knock-out
mice, however there was a low treatment number in the
study and a statistical difference was not detected [30].
The observed increase in lxr and putative activity of
LXR may be related to the observed hyperglycemia,
since some studies implicate LXR as a glucose sensor,
which binds glucose with similar affinity as oxysterols
[63]. Similar to the previously discussed metabolic
markers, time course studies are needed to delineate po-
tential time-specific effects from true species-specificdifferences for the regulation of genes implicated in
cholesterol metabolism. For example, while the expres-
sion of several genes implicated in cholesterol biosyn-
thesis was decreased 1 d following the last injection of
LNA-122i in mice, this effect was not observed 1 wk fol-
lowing the last injection of LNA-122i, in spite of a stably
maintained decrease in plasma cholesterol concentra-
tions [11].
Conclusion and future perspectives
Inhibition of miRNA-122 in rainbow trout results in
metabolic changes that are qualitatively similar to
changes observed in mammalian models. However,
quantitative differences, for example in postprandial glu-
cose concentrations, may represent species-specific dif-
ferences, which appear to be more pronounced in trout
compared to previous mammalian studies. Mechanistic-
ally, the increased hyperglycemia does not appear to be
related to hepatic glucose supply, favoring the hypothesis
of decreased hepatic glucose utilization. Indeed, the sig-
nature of specific components, notably reductions in
liver gk expression, as well as reduction of hepatic FAS
protein abundance, are in line with the proposed hy-
pothesis that miRNA-122 regulates glucose homeostasis
via modulation of glycolytic flux towards de novo lipo-
genesis. The regulation of these genes appears to be in-
dependent of the insulin signaling pathway, and is likely
related to as of yet unidentified direct targets. Our in
silico analysis of predicted miRNA-122 targets in trout
revealed a strong enrichment for cell cycle, proliferation
and differentiation processes. Given that these miRNA-
122 targets are conserved between trout and mice, and
that cell-cycle regulators are proposed to cross-talk with
metabolic pathways [64], genes involved in this group
may be good candidates for mediating metabolic effects.
As well, predicted miRNA-122 targets in trout were
enriched for functions in glucose metabolism (insulin
growth factor 2, igf2; atrial natiuretic peptide, anp;
interleukin-15 receptor alpha chain, il15ra; uncoupling
protein 2, ucp2; glucose transporter 1a, glut1a; growth
hormone 2, gh2; cellular differentiation marker 80, cd80;
suppressor of cytokine signaling 6, socs6), a result that
may indicate direct regulation of glucose metabolism by
miRNA-122 in trout. However, the distinct roles of these
genes in trout have not been characterized with regard
to glucose metabolism, but present an interesting avenue
for future study. While our study is the first to
characterize metabolic effects of the conserved miRNA-
122 in a non-mammalian vertebrate, future detailed
time-course studies are needed to fully differentiate be-
tween true species-specific differences, and time-
dependent effects of miRNA-122 action, especially given
that the metabolic functions of miRNA-122 have been
shown to underlie circadian regulation in mammals [65].
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In silico approaches
Analysis of pre-miR-122 sequences in fish and vertebrate
genomes
Sequences of miRNA-122 were obtained by BLAST analysis
of the zebrafish pre-miRNA-122 genome sequence against
genome sequences available in the ENSEMBL database
(www.ensembl.org). Following this approach we retrieved
pre-miRNA-122 sequences from the African clawed frog
(Xenopus leavis) [ENSXETG00000028985], the Carolina
anole (Anolis carolinensis) [ENSACAT00000018998], the
red jungle fowl (Gallus gallus [ENSGALG00000018343],
the human (Homo sapiens) [ENSG00000207778], the field
mouse (Mus musculus) [ENSMUSG00000065402], the
West Indian ocean coelacanth (Latimeria chalumnae)
[JH127895.1 9514 to 9584 (+)], the Atlantic cod (Gadhus
morua) [contig56666 645 to 717 (+)], the green spotted
puffer (Tetraodon nigroviridis) [ENSTNIT00000023441],
the fugu (Takifugu rupipres) [ENSTRUG00000018785], the
three-spined stickleback (Gasterosteus aculeatus) [group
XIV 3950425 to 3950502 (+)], the Japanese rice fish (Ory-
zias latipes) [ENSORLG00000020901] and the common
platy (Xiphophorus maculatus) [JH556689.1 363573 to
363653 (+)]. The same approach was taken for the elephant
shark (Callorhinchus milii) [AAVX01098255.1] using the
elephant shark genome project (http://catfishgenome.imcb.
astar.edu.sg), the catfish (Ictalurus punctatus) [FI859091],
using the catfish genome database (www.catfishgenome.
org/catfish/cbarbel), the Atlantic salmon (Salmo salar),
using the salmon database (http://genomicasalmones.dim.
uchile.cl) [AGKD01016205.1 and AGKD01081167.1], the
rainbow trout, using the INRA rainbow trout genome re-
sources (Y. Guiguen, personal communication), and the
gilthead sea bream (Sparus aurata) [AM950993.p.sb.5],
using the INRA Sigenae database (www.sigenae.org), re-
spectively. The genomic pre-miRNA-122 sequences were
aligned using ClustalW2 (www.ebi.ac.uk/Tools/msa/
clustalw2).
Prediction of omy-miR-122 mRNA targets
Compared to species whose genomes have been com-
pletely assembled and annotated, predictions of miR-122
binding sites in 3′UTRs of rainbow trout suffer from the
caveat that only a limited number of 3′UTRs have been
published in rainbow trout. This problem is exacerbated
by the presence of teleost genome duplications, resulting
in a higher number of protein-coding genes compared
to higher vertebrates [66]. Nevertheless, since miRNA-
target relationships may undergo substantial species-
specific evolutionary changes [67], we obtained available
annotated rainbow trout 3′UTR sequences (n = 1059)
from the UTR database (www.utrdb.ba.itb.cnr.it), in
order to assure a species-specific target prediction. Of
the retrieved annotated rainbow trout 3′UTRs, weselected sequences that contained a perfect seed match
(n = 83) corresponding to nucleotides 2–7 of the
miRNA-122. This approach was chosen, since the se-
quence of miRNA-122 is completely conserved in verte-
brate evolution (Figure 1), implicating the same seed is
functional in trout as in mammals. In studies using
mammalian models, a 2–3 fold enrichment for this se-
quence motif has been shown in the 3′UTRs of up-
regulated mRNA following miRNA-122 inhibition [9,11],
and, similarly, in the 3′UTR of mRNA transcripts corre-
sponding to identified upregulated proteins following
miRNA-122 inhibition [31]. To gain insight into the po-
tential functional roles of these predicted targets in rain-
bow trout, we identified human homologous sequences
using Uniprot ID (www.uniprot.org/). This approach re-
sulted in the successful mapping of 76 predicted rainbow
trout target genes to mammalian homologs. Based on
these identified mammalian homologs, a sub-network
enrichment analysis (SNEA) was performed in Pathway
Studio 9.0 (Ariadne, Rockville, MD, USA) and ResNet
9.0. SNEA was performed to identify gene networks that
were significantly enriched with whose mRNAs con-
tained predicted miRNA-122 target sites. Briefly, SNEA
builds sub-networks starting from a central seed from
molecular relationships (e. g., expression or binding).
These data are retrieved from the ResNet 9 database,
which is compiled by Ariadne using the MedScan data-
base. The MedScan database contains over 20 million
PubMed abstracts and approximately 900 K full-text ar-
ticles. This is followed by a statistical comparison be-
tween the sub-network and a background distribution of
known gene networks using a Mann–Whitney U-Test,
generating a p-value that indicates the statistical signifi-
cance of the difference between these two distributions
(additional details on the method can be found in the
technical bulletin p. 717 from Pathway Studios 7.0). The
enrichment p-value was set at p < 0.05. This approach
has been previously applied for the identification of gene
and protein networks in teleost fishes [68,69].
Fish and experimental design
The experiments were carried out in accordance with
the clear boundaries of EU legal frameworks, specifically
those relating to the protection of animals used for sci-
entific purposes (i.e. Directive 2010/63/EU), and under
the French legislation governing the ethical treatment of
animals (Decret no. 2001–464, May 29th, 2001). The in-
vestigators carrying out the experiment had “level 1” or
“level 2” certification, bestowed by the Direction Dépar-
tementale des Services Vétérinaires (French vetinary ser-
vices) to carry out animal experiments (INRA 2002–36,
April 14th, 2002). The experiment was conducted at
INRA facilities in Donzaq, certified for animal services
under the permit number A64.495.1 by the French
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Trout eggs were incubated until hatching and alevins
reared in 8˚C stream water at the INRA experimental
facility in Les Athas, France. Once fish reached the ju-
venile stage, animals were transferred to the INRA ex-
perimental facility at Donzacq, France, where they were
maintained in 18˚C oxygenated spring water. Juvenile
trout (n = 6) with an average weight of 20 g were distrib-
uted in three 50 l tanks and subjected to 3 intraperito-
neal (i.p.) injections per week of either teleost physiological
saline (0.6%), or 12.5 μg/g and 25 μg/g body weight of
LNA-122i (Locked Nucleic Acid miRNA-122 inhibitor;
Exiqon, Vedbæk, Denmark) respectively, dissolved in
physiological saline (Figure 10). The LNA-122i is an oligo-
nucleotide with the specific sequence 5′ ATTGTCA-
CACTCC 3′ which contains phosphorothioate backbones
to improve in vivo stability and distribution [70]. A short
(13 nt) LNA-122i was chosen to inhibit all described rain-
bow trout miRNA-122 isomiRNAs. In addition to the com-
pletely conserved omy-miRNA-122 identified from trout
genomic sequences (Figure 1), additional isomiRNAs shar-
ing the same functional seed sequence, but differing in
their 3′nucleotides have been identified through next gen-
eration sequencing in trout, likely resulting from posttran-
scriptional modification of the primary transcript [13].
Therefore, in an effort to inhibit all omy-miRNA-122 iso-
miRNAs, an inhibitor was chosen which contains the re-
verse complement of the seed region (nucleotides 2–7 of
all identified omy-miRNA-122 isomiRNAs, but does not
discriminate between alternate 3′ nucleotide sequences.
Trout were not fed prior to injections and, following the
last injection, rainbow trout were fed ad libitum in the
morning and evening for 4 days. On the fifth day, fish were
fed in the morning and sacrificed four hours after the meal,
and liver tissue was collected and flash frozen in liquid ni-
trogen and subsequently stored at −80˚C until further
analysis. This postprandial timeframe for the experi-
mental protocol was based on previous studies in rain-
bow trout, that had revealed a postprandial increase in
hepatic expression of omy-miRNA-122b isomiRNA in
rainbow trout 4 h after feeding [14], in addition to acti-
vation of the hepatic insulin pathway and regulation of
metabolic gene expression. The number and doses of
the LNA-122i injections were based on previous stud-
ies in mice [11], which revealed functional inhibition
of miRNA-122 and associated metabolic effects at
doses between 12.5 μg/g and 25 μg/g up to one week
after the last injection.Plasma metabolic profile
Plasma glucose (Glucose RTU, BioMérieux, Marcy l′
Etoile, France), triglycerides (PAP 150, BioMérieux),
free fatty acids (NEFA C kit, Wako Chemicals, Neuss,Germany), and cholesterol (Cholesterol RTU, BioMér-
ieux) concentrations were determined using commer-
cial kits adapted to a microplate format, according to
the recommendations of the manufacturer.
Total RNA extraction and cDNA synthesis
Relative hepatic gene expression was determined by
quantitative real-time RT-PCR. The extraction of total
RNA was performed using the Trizol reagent (Invitro-
gen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. An amount of 1 μg of total RNA
was used for cDNA synthesis. The NCode™ VILO™
miRNA cDNA synthesis kit (Invitrogen), or the Super-
Script III RNAse H– Reverse transcriptase kit (Invitro-
gen) with random primers (Promega, Charbonniéres,
France), were used to synthesize cDNA (n = 6 for each
treatment) for miRNA and mRNA, respectively.
Real-time RT PCR
For gene expression assays, forward primer sequences
for miRNAs were taken directly from the sequence in-
formation provided by Salem and colleagues [13], or, if
not available, designed based on miRNA sequences
found in the trout genome. The universal reverse primer
used for all miRNA expression analysis was provided by
the manufacturer with the NCode™ VILO™ miRNA
cDNA synthesis kit (Invitrogen). The primer sequences
used in the real-time RT-PCR assays for miRNAs and
metabolic genes, as well as the conditions of the assays
have been previously described [14,40,58,71]. For gene
targets that had not been previously validated, primer se-
quences, specific assay conditions and available acces-
sion numbers from Genebank (www.ncbi.nlm.nih.gov/
genbank) or the INRA trout EST database SIGENAE
(www.sigenae.org) are shown in Table 2. For real-time
RT-PCR assays of miRNAs, the Roche Lightcycler 480
system was used (Roche Diagnostics, Neuilly-sur-Seine,
France). The assays were performed using a reaction
mix of 6 μl per sample, consisting of 2 μl of diluted
cDNA template, 0.12 μl of each primer (10 μM), 3 μl
Light Cycler 480 SYBR® Green I Master mix, and 0.76 μl
DNAse/RNAse free water (5 Prime GmbH, Hamburg,
Germany). The PCR protocol was initiated at 95°C for
10 min for initial denaturation of the cDNA and hot-
start Taq-polymerase activation, followed by 45 cycles of
a two-step amplification programme (15s at 95°C; 40 s
at 60–64°C), according to the primer set used. Melting
curves were systematically monitored (temperature gra-
dient at 1.1°C/10 s from 65–94°C) at the end of the last
amplification cycle to confirm the specificity of the amp-
lification reaction. Each PCR assay included replicate
samples (duplicate of reverse transcription and PCR
amplification, respectively) and negative controls (re-
verse transcriptase- and cDNA template-free samples).
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genes have been described previously [14]. As for omy-
miRNA SYBR Green assays, melting curves were sys-
tematically monitored (temperature gradient at 0.5°C/
10 s from 55–94°C at the end of the last amplification
cycle), to confirm the specificity of the amplification re-
action. Each PCR run included replicate samples and
controls as described above. The specificity of reactions
used to amplify previously uncharacterized amplicons
was further confirmed by sequencing of the PCR prod-
uct (Beckman-Coulter, Hope End Takeley, Essex, UK),
followed by a BLAST search of the obtained sequences
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). For the expres-
sion analysis of miRNA and mRNA, relative quantifica-
tion of target gene expression was performed using gene
expression values of u6 and ef1α for the normalization
of measured hepatic miRNAs and mRNAs, respectively,
as neither gene expression values changed significantly
between treatment groups (data not shown). In all cases,
PCR efficiency (E) was measured by the slope of a stand-
ard curve using serial dilutions of cDNA and PCR effi-
ciency values ranged between 1.8 and 2.2, corresponding
to 90-110% efficiency.
Western blotting
Frozen liver samples (~300 mg) were homogenized on
ice with an Ultraturrax homogenizer (IMLAB Sarl, Lille,
France). During homogenization, samples were kept in a
buffer containing 150 mmol l−1 NaCl, 10 mmol l−1 Tris,
1 mmol l−1 EGTA, 1 mmol l−1 EDTA (pH 7.4), 100
mmol l−1 sodium fluoride, 4 mmol l−1 sodium pyrophos-
phate, 2 mmol l−1 sodium orthovanadate, 1% (v/v) Tri-
ton X-100, 0.5% (v/v) NP40-IGEPAL, and a protease
inhibitor cocktail (Roche, Basel, Switzerland). Homoge-
nates were centrifuged at 1000 g for 30 min at 4°C, and
supernatants were then centrifuged for 45 min at
15.000 g. The resulting supernatants (n = 6 for each time
point) were stored at −80°C. Protein concentrations were
determined using the Bio-Rad Protein assay kit (BIO-
RAD, Hercules, CA, USA). According to the protein,
quantities of 5–20 μg protein per sample were subjected
to SDS-PAGE and Western Blotting, using the appropri-
ate antibodies. All primary antibodies used for analysis
of the insulin signaling pathway were obtained from Cell
Signaling technologies (Ozyme, Saint Quentin Yvelines,
France), while antibodies used for the measurement of
GK, and FAS were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). All antibodies have been
shown to cross-react successfully with rainbow trout
proteins of interest [21,40,50,72,73]. All primary anti-
bodies used were raised in rabbit, and after final wash-
ing, membranes were incubated with an IRDye infrared
secondary anti-rabbit antibody raised in goat (LI-COR
Inc. Biotechnology, Lincoln, NE, USA). Bands werevisualized and quantified by Infrared fluorescence using
the Odyssey® Imaging System (LI-COR Inc. Biotechnol-
ogy, Lincoln, NE, USA).
Statistical analysis
Data were analyzed by univariate ANOVA. In cases
where data were nonparametric or not homoscedastic,
data transformations were used to meet ANOVA cri-
teria. Normality was assessed using the Shaprio-Wilk
test, while homoscedasticity was determined using
Levene’s test. Following univariate ANOVA analysis, The
Student-Newman-Keuls test was used for post-hoc ana-
lysis. Data were analysed using the R software/R Com-
mander package.
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mRNA targets.
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